EpiVario Inc. — SEC Form D Filing
EpiVario Inc. filed an SEC Form D on October 13, 2026, reporting $185K raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 13, 2026
- Amount reported
- $185K
- Round stage
- Pre-seed stage based on the small $185,000 debt raise intended for early research and operational runway.
- Industry
- Pharmaceuticals
- Website
- https://www.epivario.com
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Neuropsychiatric and addiction disorders often resist conventional treatments because existing therapies fail to target underlying epigenetic dysregulation.
Solution
EpiVario develops targeted pharmaceutical drug candidates designed to modify disease-related epigenetic processes to treat trauma, stress, and substance-use disorders.
Why now
Recent advances in understanding chromatin biology and epigenetic gene regulation enable precise pharmacological control over psychiatric gene expression and memory consolidation.
Source: SEC EDGAR Form D filing